Docetaxel ADVAGEN approved in Singapore
13 March 2018
ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Docetaxel ADVAGEN, is now approved in Singapore.
"We are happy to have Docetaxel ADVAGEN registered and approved in Singapore. We hope to make the product available to doctors and patients at the earliest," said Koh of ADVAGEN. "This will provide the doctors and patients with a safe, effective and also a more affordable treatment option."
ADVAGEN is founded in 2006 with the aim of providing safe, effective and affordable healthcare solutions that improve the health of our users, patients and support healthcare professionals in discharging their responsibilities. It comprises a team of dedicated and motivated professionals driven by the passion to provide these solutions for the benefit of all people. This commitment helps us add value to the lives of our users, patients and healthcare professionals alike.
Over the years, we have brought healthcare solutions that focus on pertinent health issues and are highly effective in disease containment, prevention and health recovery. Our product portfolio consists of both health supplements and pharmaceuticals. For pharmaceuticals, the main therapeutic area we focus on is oncology and haematology. And for health supplements, the focus is on gastrointestinal and immunity.
The medical fraternity recognizes ADVAGEN for its high-quality products. Our products are recommended and used by leading medical practitioners in hospitals and medical centres.
ADVAGEN strives to provide safe, effective and affordable healthcare solutions to our users, patients and healthcare professionals. Our aim is to make a positive impact on the health and thereby the development of societies and communities across the markets we operate in. We like to continuously improve our products and services for the well-being of people. Adding Value to Lives is the very spirit of all our endeavours.